Tempus AI
The world's largest clinical-molecular AI platform powering precision oncology decisions for physicians and pharma.
Overview
Tempus AI is a Chicago-based health technology company that has built the world's largest library of de-identified clinical and molecular data — spanning genomics, pathology imaging, and real-world patient outcomes — and combines it with proprietary AI models to help oncologists make more precise treatment decisions. Its platform connects to approximately 50% of US oncologists and over 4,500 hospitals, offering next-generation sequencing diagnostics, AI-assisted biomarker prediction from tissue slides (via the Paige Predict suite acquired in 2025), clinical trial matching through the TIME Network, and a physician-facing agentic AI portal called Hub.
Beyond direct clinical use, Tempus licenses its multimodal datasets to more than 200 pharmaceutical and biotech companies through its Lens platform, enabling drug discovery, trial design, and real-world evidence generation. The company went public on Nasdaq (TEM) in June 2024 and reported Q2 2026 revenue of $382.5 million — a 22% year-over-year increase and its first GAAP-profitable quarter — with full-year 2026 guidance raised to $1.595 to $1.605 billion. Its international footprint is anchored by SB Tempus, a joint venture with SoftBank established in 2024 to bring precision medicine AI to Japan.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 4 Sep 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Rent or license multimodal oncology data
- Agentic AI analysis tools
- Used by 19 of the top 20 biopharma companies
- Large-scale dataset licensing
- Contract research operations
- Custom multi-year terms
Use cases
What you can produce with Tempus AI
- NGS genomic sequencing report identifying mutations, fusions, and copy number variants mapped to actionable therapies and FDA-approved treatments
- AI-generated biomarker prediction panel from a single H&E whole-slide image covering 123 biomarkers across 16 cancer types (Paige Predict, ~5 min turnaround)
- Clinical trial match list identifying eligible open trials for a patient's specific molecular and clinical profile via the TIME Network
- De-identified multimodal research dataset (genomics, clinical outcomes, imaging) licensed to pharma teams through the Lens platform
- Hub-generated prior authorization letters and patient-specific clinical summaries drawn from Tempus genomic and longitudinal data
- Minimal residual disease (MRD) monitoring results for tracking treatment response and early recurrence detection in cancer patients
ASEAN Perspective
Tempus AI in Southeast Asia
Tempus AI has no disclosed commercial operations or data partnerships in Southeast Asia as of mid-2026; its only confirmed Asia presence is the SB Tempus joint venture in Japan, established with SoftBank in June 2024, focused on aggregating Japanese clinical and molecular data. ASEAN health systems seeking AI-powered genomics infrastructure will need to look at regional players or Illumina's local distributor network in the interim. Tempus's pharma-facing Lens data platform could theoretically be licensed to APAC biopharma companies, but the data itself is predominantly US-sourced, limiting clinical relevance for Asian patient populations with distinct mutational profiles.
Tempus AI sits on one of the more defensible data moats in health AI — a self-reinforcing loop of clinical sequencing, molecular data, and real-world outcomes that's hard for pure-software competitors to replicate. Q1 2026 revenue of $348M (36% YoY, 63.8% gross margin) and Adjusted EBITDA of -$2.8M, up sharply from -$16.2M a year earlier, show the model maturing. The Paige acquisition extends it into digital pathology.
The caveats are structural. Pricing runs entirely through enterprise sales — no public rate card, no self-serve tier. GAAP net loss widened to $0.71/share on stock-comp and unrealized investment losses even as non-GAAP EPS of -$0.13 beat the -$0.20 estimate, a split worth reading carefully rather than taking either number at face value. Outside the US, the SB Tempus Japan joint venture is the only confirmed foothold; Southeast Asia has no disclosed presence.
What people say
$348 million. That's what Tempus AI booked in Q1 2026 revenue, up 36% year-over-year, with Diagnostics ($261M) still the bigger engine and Data and Applications ($87M) growing faster at 40.5%. Management raised full-year guidance to $1.59–1.60 billion off the back of it.
The data moat is real: roughly half of US oncologists and 4,500+ hospitals route through the platform, and the January 2026 Paige acquisition folds digital pathology into the same pipeline — tissue-slide biomarker prediction sitting next to genomic sequencing and a physician-facing AI portal called Hub. On the pharma side, Lens has more than $1.1 billion in signed data-licensing contract value as of December 2025, spread across 200+ partners.
Profitability is the asterisk, and the numbers are genuinely confusing unless you separate GAAP from non-GAAP. Adjusted EBITDA came in at -$2.8 million (versus -$16.2 million a year earlier), and non-GAAP EPS of -$0.13 beat the -$0.20 consensus. But GAAP net loss widened to $0.71 per share, driven mostly by stock compensation and unrealized losses on marketable securities — not the operating business getting worse.
Geographically this is a US story with one confirmed export: the SB Tempus joint venture with SoftBank in Japan. There's no disclosed Southeast Asia presence and no self-serve pricing tier — everything runs through enterprise sales, which puts Tempus out of reach for smaller clinics or APAC health systems working with limited budgets.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Tempus was founded in 2015 after CEO Eric Lefkofsky's wife was diagnosed with breast cancer — he was frustrated by how little AI was being applied to cancer care decisions.
- Paige's foundation model for cancer pathology was trained on almost 7 million digitized slide images, earning it the title of the first million-slide foundation model for cancer.
- The SB Tempus joint venture launched in June 2024 with SoftBank, each investing JPY 15 billion (~$100M USD), signalling precision medicine's push into Japan's aging population market.
- Paige Predict, launched January 2026, can predict the likely presence or absence of 123 biomarkers across 16 cancer types from a single H&E tissue slide — in roughly 5 minutes.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Tempus AI's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Tempus AI unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Tempus AI directly →
Spotted something out of date? Suggest an update →
Alternatives to Tempus AI
More in Research & Data
